Skip to main content
. 2020 Aug 14;13(8):194. doi: 10.3390/ph13080194

Table 2.

Clinical evaluation of activity of PN and its derivatives.

Phase Purpose Clinical Trial Registry
PN I pharmacokinetics and toxicity none [18]
DMAPT I AML, ALL, and other blood-lymph tumors none [unpublished]
(United Kingdom)
ACT001 I/II safety, tolerability, pharmacokinetics,
recurrent glioblastoma
ACTRN12616000228482
(Australia & New Zealand)
ChiCTR-OIC-17013604
(China)